Ovarian Cancer Genetic Testing

Ovarian Cancer is a disease that all women fear.  The fear is based on the fact that the symptoms of the disease typically do not manifest until the disease reaches advanced stages, at which time it is virtually incurable.

Ovarian cancer  accounts for 3% of all cancers among U.S. women and is the second most common gynecological cancer.  The American Cancer Society estimates that there are approximately 22,000 new cases of ovarian cancer each year.  About 15,000 women are expected to die of the disease annually.  Ovarian cancer kills more women than all of the other gynecolical cancers combined and is the fourth leading cause of cancer deaths among women in the United States.

PreOvar™ tests for the KRAS-variant, and will help identify ovarian cancer patients whose female relatives should also be evaluated for the KRAS-variant. PreOvar™ may also help assess the relative risk of developing ovarian cancer for women who have a family history of ovarian cancer without a living proband (ancestor with the disease). The KRAS-Variant is present in 6-10% of the general population and 25% of non-selected women with epithelial ovarian cancer. Additionally, the KRAS-variant was identified in over 60% of Hereditary Breast and Ovarian Cancer (HBOC) patients that were previously classified as “uninformative,” or negative for other known genetic markers of ovarian cancer risk. For more information please visit http://www.miradx.com.